Figure 4.

Co–infusion of the MAP kinase inhibitor U0126 partially blocked the effects of MBH insulin on the suppression of hGP without affecting glucose disposal. (A) Suppression of hGP and (B) glucose disposal measured with tracer dilution methodology during a 1mU · kg⁻¹ · min⁻¹ clamp in rats receiving an infusion of either aCSF (vehicle), insulin, insulin + PI3K inhibitor LY 294002 or insulin + MAPK inhibitor U0126 into the MBH. (C) Plasma insulin levels at baseline (−120 to 120 min pre–clamp period) and during the clamp (120–240 min). (D) Glucose levels prior to and during the clamp. (E, F) Glucose infusion rate (GIR) required to maintain euglycemia. Data are shown as mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ^#p < 0.05 comparing MBH Insulin + LY294002 vs. MBH Vehicle by Student's unpaired t test; n ≥ 4 per group.